Biopharma Competition FDA Sales 
European Pharmaceutical Review
AUGUST 21, 2023
Q2 2023 biopharma market capitalisation results Eli Lilly “Eli Lilly witnessed the largest market capitalisation growth of 36.1 Lilly completes biopharma acquisitions GlobalData highlighted that Eli Lilly reported its synthetic peptide Mounjaro had $980 million in global sales in Q2. trillion in the Q1 of 2023 to $3.56
European Pharmaceutical Review
DECEMBER 6, 2022
According to a market report by GlobalData, expanding generic drug competition and a drop in demand for COVID-19 vaccines and therapies have lowered the aggregate market capitalisation of the global top 20 biopharmaceutical companies by 9.1 percent from $3.45 trillion in Q2 2022 to $3.14 trillion in Q3 2022. percent and 24.2 percent and 16.2
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 20, 2022
The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. The FDA also awarded priority review for Eli Lilly’s donanemab, a monoclonal antibody for Alzheimer’s disease, in August 2022, and the company expects approval by February 2023. trillion in Q2 2022 to $3.14
Pharmaceutical Technology
FEBRUARY 8, 2023
The top 20 companies in the global biopharma industry saw 5.4%* aggregate market capitalization from $3.43 The company’s blockbuster immunotherapy oncology drug, Keytruda, a monoclonal antibody that targets PD-1, continues to reap record sales with an analyst consensus global sales forecast of $20.8 trillion to $3.61 to $365.84.
pharmaphorum
NOVEMBER 24, 2022
Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA’s decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC). Mirati has declined to comment on the speculation.
Clarivate
JANUARY 23, 2024
forecast peak sales per asset versus the cost of developing an asset or an output measure such as the number of global first world launches). In addition, R&D productivity analyses are in some way associated with actual or future launches or a consequence of the launch, such as resulting sales.
pharmaphorum
DECEMBER 28, 2022
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009.
Expert insights. Personalized for you.
79 
Let's personalize your content